CytoDyn (OTCQB: CYDY) is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection, according to the company’s website (see here: www.CytoDyn.com). SNNLive spoke with Dr. Nader Pourhassan, President & CEO of CytoDyn, Inc., at the LD Micro Invitational 2016 in Bel Air, CA.
In this video interview, Dr. Pourhassan and our host discuss the following topics:
- Overview of CytoDyn Inc.
- Discusses clinical developments
- What differentiates the company’s drug from what is currently on the market
- Size of market
- Where the science was developed and phase 3 trials taking place
- Dr. Pourhassan’s background
For more information about CytoDyn Inc., please visit: www.CytoDyn.com
The interview may contain forward looking statements about CytoDyn Inc. See CytoDyn's periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions